AXSOME THERAPEUTICS, INC. Finance Lease, Weighted Average Discount Rate, Percent
AXSOME THERAPEUTICS, INC. (AXSM) had Finance Lease, Weighted Average Discount Rate, Percent of 9.15% as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Leases
us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-10
- 2026-06-30: Finance Lease, Weighted Average Discount Rate, Percent 9.15%.
- 2026-03-31: Finance Lease, Weighted Average Discount Rate, Percent 2.90%.
- 2025-12-31: Finance Lease, Weighted Average Discount Rate, Percent 9.60%; Finance Lease, Weighted Average Discount Rate, Percent as first filed 2.80%.
- 2025-09-30: Finance Lease, Weighted Average Discount Rate, Percent 9.60%.
| Period end | Finance Lease, Weighted Average Discount Rate, Percent | Finance Lease, Weighted Average Discount Rate, Percent as first filed |
|---|---|---|
| 2026-06-30 | 9.15% 10-Q · filed 2026-08-10 | |
| 2026-03-31 | 2.90% 10-Q · filed 2026-05-04 | |
| 2025-12-31 | 9.60% 10-Q · filed 2026-08-10 | 2.80% 10-K · filed 2026-02-23 |
| 2025-09-30 | 9.60% 10-Q · filed 2025-11-03 | |
| 2025-06-30 | 9.60% 10-Q · filed 2025-08-04 | |
| 2025-03-31 | 9.50% 10-Q · filed 2025-05-05 | |
| 2024-12-31 | 9.00% 10-K · filed 2025-02-18 | |
| 2024-09-30 | 9.60% 10-Q · filed 2024-11-12 | |
| 2024-06-30 | 9.60% 10-Q · filed 2024-08-05 | |
| 2024-03-31 | 9.70% 10-Q · filed 2024-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |